Biotech firm shows the way onto the global stage
InvitroCue debuts on the ASX just four years after its birth; sales growth has doubled and is 'sustainable', says founder
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
SUCCESS stories in the Singapore life sciences sphere are few and far between, but InvitroCue, which targets profitability in seven years, could light the way for other homegrown biotechnology firms seeking to get on the global stage.
The biotech firm, a spin-off from the Agency for Science, Technology and Research (A*Star), helps drug-makers determine which vaccines, products or devices are safe to use in humans - even before tests are conducted to determine if they work.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Beijing’s calculated silence on the Iran war
Middle East-linked energy supply shocks put Asean Power Grid back in focus
